LUPE YEPEZ- MICHEL: Open Payments
NPI 1952481053 · VENTURA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,971 in 35 payments from 18 companies in 2025. Trend: 2023 $1,100 · 2024 $1,552 · 2025 $2,971
Food & beverage: $2,971
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $598 |
| GlaxoSmithKline, LLC. | 3 | $331 |
| AstraZeneca Pharmaceuticals LP | 2 | $250 |
| Madrigal Pharmaceuticals | 2 | $241 |
| ABBVIE INC. | 2 | $226 |
| Amgen Inc. | 2 | $223 |
| Ardelyx, Inc. | 1 | $130 |
| Alkermes, Inc. | 1 | $129 |
| ACADIA Pharmaceuticals Inc | 1 | $121 |
| Neurocrine BioSciences, Inc. | 1 | $114 |
Products named: REZDIFFRA, Ozempic, IBSRELA, LYBALVI, AIRSUPRA, BREZTRI, Wegovy, NUPLAZID.
Industry payments across CA — which companies pay providers there.
